Disentangling risk of progression and clinical trajectories in preclinical AD: views from the International Working Group

Abstract

Background: The International Working Group (IWG) framework distinguishes two nosological categories within the cognitively unimpaired biomarker‐positive population: “presymptomatic Alzheimer's disease (AD)” (high risk of progression) and “asymptomatic at risk” (low risk) ¹ , unlike the Alzheimer's Association (AA) cri